Skip to content

Application value of ultrasonography combined with transient elastography for staging of hepatic fibrosis in patients with primary biliary cholangitis (PBC)

Application value of ultrasonography combined with transient elastography for staging of hepatic fibrosis in patients with primary biliary cholangitis (PBC)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032053
Enrollment
Unknown
Registered
2020-04-19
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary biliary cholangitis

Interventions

Gold Standard:Any two of the following items met: 1. increased biochemical indicators of cholestasis such as alkaline phosphatase
2. positive serum AMA or AMA-M2
3. hepatic histopathology.
and&#32
ultrasound?transient&#32
(TE)

Sponsors

You'an Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Case group inclusion criteria: (1) Aged 18 to 70 years; (2) The diagnosis of PBC is confirmed by the result of liver biopsy, which include the stage of liver fibrosis; (3) The patient with cirrhosis due to PBC is diagnosised by clinical indicator according to consensus on the diagnosis and management of primary biliary cirrhosis (2015); 2. Control group inclusion criteria; (1) Aged 18 to 70 years, normal transaminase levels; no previous history of heart disease, lung disease, liver disease or cancer; and no history of long-term drug use or excessive alcohol consumption; (2) Definitive diagnosis of chronic hepatitis B (CHB) and chronic hepatitis C (CHC), patients with nonalcoholic fatty liver disease (NAFLD).

Exclusion criteria

Exclusion criteria: Patients with viral hepatitis, drug hepatitis, steatohepatitis, alcoholic hepatitis, metabolic liver disease and human immunodeficiency virus infection, pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
The size of liver;The size of spleen;Hepatic stiffness;controlled attenuation parameter (CAP);

Countries

China

Contacts

Public ContactYUAN ZHANG

You'an Hospital, Capital Medical University

fyzfyz2004@163.com+86 15611886443

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026